IMNR Receives U.S. Patent on Rheumatoid Arthritis and Multiple Sclerosis Technologies
PR Newswire - December 07, 1998 08:19
CARLSBAD, Calif., Dec. 7 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received a patent from the United States Patent and Trademark Office entitled Vaccination and Methods Against Diseases Resulting from Pathogenic Responses by Specific T Cell Populations. The patent, Number 05837246, extends previous coverage for the Company's autoimmune disease technology by identifying the receptors on targeted T cells specific for rheumatoid arthritis and multiple sclerosis. This patent specifically covers Vbeta17, a beta-chain variable region of the T cell receptor that is closely associated with rheumatoid arthritis in human subjects. The Company has recently completed a Phase 2b trial using this patented technology to treat rheumatoid arthritis and anticipates releasing the results by the end of 1998.
The Immune Response Corporation, a biopharmaceutical company based in Carlsbad, California, develops immune-based therapies to induce specific T cell responses for the treatment of HIV, autoimmune diseases, and cancer. The Company is conducting clinical trials on immune-based therapies for HIV, rheumatoid arthritis, psoriasis, multiple sclerosis, colon cancer, and brain cancer, and preclinical studies for melanoma and prostate cancers. In addition, the Company is developing a delivery technology that enables intravenously injected genes to target the liver. This gene therapy program currently includes preclinical studies for the treatment of hemophilia and hepatitis.
This news release contains forward-looking statements. Actual results may vary materially from those expected due to a variety of risk factors, including the uncertainty of successful completion of clinical trials, and those risks set forth from time to time in the Immune Response Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended December 31, 1997. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
SOURCE The Immune Response Corporation
/CONTACT: Paula Margulies of The Immune Response Corporation,
760-603-3321/
/Company News On-Call: prnewswire.com or fax,
800-758-5804, ext. 434675/
/Web site: imnr.com
(IMNR)
Headlines Next Story
|
